These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25644128)

  • 41. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?
    Li-Yu J; Clayburne G; Sieck M; Beutler A; Rull M; Eisner E; Schumacher HR
    J Rheumatol; 2001 Mar; 28(3):577-80. PubMed ID: 11296962
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
    Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gout medication treatment patterns and adherence to standards of care from a managed care perspective.
    Sarawate CA; Brewer KK; Yang W; Patel PA; Schumacher HR; Saag KG; Bakst AW
    Mayo Clin Proc; 2006 Jul; 81(7):925-34. PubMed ID: 16835972
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Febuxostat efficacy in allopurinol-resistant tophaceous gout.
    Uh M; Reid G
    J Clin Rheumatol; 2011 Jun; 17(4):204-6. PubMed ID: 21617552
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
    Stamp L; Gow P; Sharples K; Raill B
    Aust N Z J Med; 2000 Oct; 30(5):567-72. PubMed ID: 11108066
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Allopurinol adherence among patients with gout: an Italian general practice database study.
    Mantarro S; Capogrosso-Sansone A; Tuccori M; Blandizzi C; Montagnani S; Convertino I; Antonioli L; Fornai M; Cricelli I; Pecchioli S; Cricelli C; Lapi F
    Int J Clin Pract; 2015 Jul; 69(7):757-65. PubMed ID: 25683693
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Improved management of acute gout during hospitalization following introduction of a protocol.
    Kamalaraj N; Gnanenthiran SR; Kathirgamanathan T; Hassett GM; Gibson KA; McNeil HP
    Int J Rheum Dis; 2012 Dec; 15(6):512-20. PubMed ID: 23253233
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Variation in gout care in Aotearoa New Zealand: a national analysis of quality markers.
    Jackson G; Dalbeth N; Te Karu L; Winnard D; Gow P; Gerard C; Minko N
    N Z Med J; 2014 Oct; 127(1404):37-47. PubMed ID: 25331310
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
    N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Diagnosis and treatment of gout: not always simple].
    van Vugt RM; Jacobs JW; Bijlsma JW
    Ned Tijdschr Geneeskd; 1996 Jan; 140(4):177-9. PubMed ID: 8618639
    [No Abstract]   [Full Text] [Related]  

  • 51. Updates in the management of gout.
    Keith MP; Gilliland WR
    Am J Med; 2007 Mar; 120(3):221-4. PubMed ID: 17349440
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The current state of care in gout: Addressing the need for better understanding of an ancient disease.
    Zychowicz ME; Pope RS; Graser E
    J Am Acad Nurse Pract; 2010 Nov; 22 Suppl 1():623-36. PubMed ID: 21054636
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel.
    Zandman-Goddard G; Amital H; Shamrayevsky N; Raz R; Shalev V; Chodick G
    Rheumatology (Oxford); 2013 Jun; 52(6):1126-31. PubMed ID: 23392592
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and efficacy of allopurinol in chronic kidney disease.
    Thurston MM; Phillips BB; Bourg CA
    Ann Pharmacother; 2013 Nov; 47(11):1507-16. PubMed ID: 24259601
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Factors associated with acute gout attacks in normouricaemic gout patients receiving allopurinol: a retrospective study.
    So MW; Lee SG; Kim YG; Lee CK; Yoo B
    Scand J Rheumatol; 2011 Nov; 40(6):444-7. PubMed ID: 21916803
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chronic kidney disease in gout in a managed care setting.
    Fuldeore MJ; Riedel AA; Zarotsky V; Pandya BJ; Dabbous O; Krishnan E
    BMC Nephrol; 2011 Aug; 12():36. PubMed ID: 21812963
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluating appropriate use of prophylactic colchicine for gout flare prevention.
    George M; Pullman-Mooar S; Hussain F; Schumacher HR
    Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1258-62. PubMed ID: 24376081
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patient-reported gout attack frequency and allopurinol use in general practice in the Netherlands: a prospective observational cohort study protocol.
    van Leeuwen KDB; Bohnen AM; Jacobs ML; van Der Lei J; Janssens HJEM; Koffeman AR; Bindels PJE; Bierma-Zeinstra SMA
    BMJ Open; 2018 Nov; 8(11):e024335. PubMed ID: 30478125
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.
    Dalbeth N; Stamp L
    Semin Dial; 2007; 20(5):391-5. PubMed ID: 17897242
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of gout.
    Cohen MG
    Intern Med J; 2011 Jan; 41(1a):70-1. PubMed ID: 21265967
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.